<DOC>
	<DOCNO>NCT02950064</DOCNO>
	<brief_summary>This phase 1 , Open-label , multicenter Dose Escalation study BTP-114 , novel platinum product , patient advance solid tumor BRCA DNA repair mutation . This clinical study comprise 2 sequential part : Part 1 ( Dose Escalation ) Part 2 ( Expansion ) . The purpose study evaluate safety , pharmacokinetics anti-cancer activity BTP-114 .</brief_summary>
	<brief_title>A Study Determine Safety BTP-114 Treatment Patients With Advanced Solid Tumors With BRCA Mutations</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>INCLUSION : All Patients 1 . Male female age ≥18 year . 2 . ECOG PS score 01 . 3 . Adequate organ function . 4 . Ability understand willingness sign inform consent form prior initiation study procedure . 5 . Measurable disease per RECIST , OR patient primary diagnosis castration resistant prostate cancer , progressive disease ( PD ) prostate surface antigen ( PSA ) image set medical surgical castration . 6 . Documented BRCA mutation , follow exception : ) Patient intend enrolled Singlepatient Cohort ; b ) Patient advance DNA repair mutationpositive solid tumor intend enrolled Expansion Cohort 5 . Patients Doseescalation Phase : 7 . Locally advanced solid tumor primary central nervous system ( CNS ) tumor patient receive ≤3 prior line 8 . Confirmed solid tumor one follow category : BRCA mutationpositive pancreatic cancer patient receive 1 prior line cytotoxic chemotherapy advance disease set . Advanced BRCA mutationpositive castrationresistant prostate cancer ( CRPC ) patient receive 2 prior line cytotoxic chemotherapy advanced disease set . Advanced BRCA mutationpositive ovarian cancer patient receive 3 prior line cytotoxic chemotherapy advanced disease set . Advanced BRCA mutationpositive triplenegative breast cancer ( TNBC ) patient receive 3 prior line cytotoxic chemotherapy advanced disease set . Advanced DNA repair mutationpositive solid tumor , include , limited BRCA nonBRCA DNA mutation , receive 3 prior line cytotoxic chemotherapy advanced disease set . DNArepair mutation may include , limited ATM , CHEK2 , PALB2 , RAD51D . Abnormal homologous repair deficiency ( HRD ) test also allow . Note dose escalation dose expansion portion study , prior target therapy include prior poly ADP ribose polymerase ( PARP ) inhibitor therapy , prior immunotherapy , prior hormonal therapy permissible . Patients castration resistant prostate cancer may receive unlimited prior hormonal therapy . EXCLUSION : 1 . History leptomeningeal disease spinal cord compression . 2 . Underwent major surgery within 4 week first treatment . 3 . Received cancerdirected therapy 14 day ( 6 week mitomycin C nitrosoureas ) start treatment . 4 . Grade 2 great peripheral neuropathy start treatment . 5 . If female , pregnant breastfeeding . 6 . Known human immunodeficiency virus ( HIV ) infection hepatitis B C infection 7 . Any primary brain tumor ( e.g. , astrocytoma , glioblastoma ) . 8 . Hypersensitivity history anaphylactic reaction platinumcontaining agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>BRCA</keyword>
	<keyword>BRCA1</keyword>
	<keyword>BRCA2</keyword>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>Castrate resistant prostate cancer</keyword>
	<keyword>Triple negative breast cancer</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>DNA repair mutation-positive solid tumor</keyword>
</DOC>